ANI Pharmaceuticals Inc (ANIP) Receives Average Rating of “Hold” from Analysts

ANI Pharmaceuticals Inc (NASDAQ:ANIP) has been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $71.00.

A number of equities analysts have recently weighed in on ANIP shares. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Canaccord Genuity set a $75.00 target price on ANI Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, December 9th. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 25th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Tuesday, November 7th. Finally, TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th.

ANI Pharmaceuticals (ANIP) traded down $0.50 during midday trading on Tuesday, reaching $59.22. The company’s stock had a trading volume of 56,382 shares, compared to its average volume of 122,503. The firm has a market cap of $690.09, a P/E ratio of 92.53 and a beta of 2.79. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $74.70. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can grew its stake in shares of ANI Pharmaceuticals by 681.8% in the 4th quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after buying an additional 2,100 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $197,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $210,000. Millennium Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $210,000. Finally, Violich Capital Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $217,000. 53.51% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://weekherald.com/2018/02/18/ani-pharmaceuticals-inc-anip-receives-average-rating-of-hold-from-analysts.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply